相似文献
1
Tesofensine and weight loss.
Lancet. 2009 Feb 28;373(9665):719; author reply 720. doi: 10.1016/S0140-6736(09)60433-5.
2
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
Ugeskr Laeger. 2009 Oct 5;171(41):2974-7.
3
Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
Curr Opin Investig Drugs. 2009 Oct;10(10):1105-16.
4
[Is there a future for medical treatment of obesity?].
Ugeskr Laeger. 2009 Oct 5;171(41):2973.
5
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Lancet. 2008 Nov 29;372(9653):1906-1913. doi: 10.1016/S0140-6736(08)61525-1. Epub 2008 Oct 22.
6
Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.
Obesity (Silver Spring). 2013 May;21(5):985-92. doi: 10.1002/oby.20122.
7
Is new hope on the horizon for obesity?
Lancet. 2008 Nov 29;372(9653):1859-1860. doi: 10.1016/S0140-6736(08)61792-4.
8
Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13.
Expert Opin Investig Drugs. 2009 Jul;18(7):1043-6. doi: 10.1517/13543780902967632.
9
The effect of tesofensine on appetite sensations.
Obesity (Silver Spring). 2012 Mar;20(3):553-61. doi: 10.1038/oby.2011.197. Epub 2011 Jun 30.
10
Under-reporting of adverse effects of tesofensine.
Lancet. 2013 Jul 13;382(9887):127. doi: 10.1016/S0140-6736(13)61563-9.
引用本文的文献
1
Pharmacological management of appetite expression in obesity.
Nat Rev Endocrinol. 2010 May;6(5):255-69. doi: 10.1038/nrendo.2010.19. Epub 2010 Mar 16.
Zotero 插件